This course will review and discuss: drugs recently approved by the regulatory bodies; drugs that have recently been unsuccessful in late stage clinical trials; new therapeutics in various phase clinical trials; clinical trials of natural products. Students will critically assess available data with a focus on new drugs and drugs in the pipeline. The goal will be to encourage students to be forward looking, self-directed learners for new therapeutics and develop a better understanding of the drug development and approval process. Weekly hours: 3 Lecture hoursRestriction(s): Completion of Year 1 of the Pharm.D. program Prerequisite(s): PHAR 290.0 Note: Students with credit for PHAR 298 topic in "New and Emerging Therapeutics" will not receive credit for this course.
This course will review and discuss: drugs recently approved by the regulatory bodies; drugs that have recently been unsuccessful in late stage clinical trials; new therapeutics in various phase clinical trials; clinical trials of natural products. Students will critically assess available data with a focus on new drugs and drugs in the pipeline. The goal will be to encourage students to be forward looking, self-directed learners for new therapeutics and develop a better understanding of the drug development and approval process. Weekly hours: 3 Lecture hoursRestriction(s): Completion of Year 1 of the Pharm.D. program Prerequisite(s): PHAR 290.0 Note: Students with credit for PHAR 298 topic in "New and Emerging Therapeutics" will not receive credit for this course.
